-
Loading metrics
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
- Camille N. Pierre ,
- Lily E. Adams ,
- Jaclyn S. Higgins,
- Kara Anasti,
- Derrick Goodman,
- Dieter Mielke,
- Sherry Stanfield-Oakley,
- John M. Powers,
- Dapeng Li,
- Wes Rountree,
- Yunfei Wang,
- Robert J. Edwards,
- S. Munir Alam,
- Guido Ferrari,
- Georgia D. Tomaras,
- Barton F. Haynes,
- Ralph S. Baric ,
- [ ... ],
-
Kevin O. Saunders
Roles Conceptualization, Formal analysis, Funding acquisition, Investigation, Supervision, Writing – original draft, Writing – review & editing
* E-mail: rbaric@email.unc.edu (RSB); kevin.saunders@duke.edu (KOS)
Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America, Department of Immunology, Duke University, Durham, North Carolina, United States of America
⨯ - [ view all ]
- [ view less ]
https://orcid.org/0000-0001-7399-7954
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
- Camille N. Pierre,
- Lily E. Adams,
- Jaclyn S. Higgins,
- Kara Anasti,
- Derrick Goodman,
- Dieter Mielke,
- Sherry Stanfield-Oakley,
- John M. Powers,
- Dapeng Li,
- Wes Rountree
x
-
- Published: June 20, 2024
- https://doi.org/10.1371/journal.ppat.1011569
- See the preprint